Vistagen receives US patent for AV-101 to treat neuropathic pain; patent exp. 2034

Vistagen Therapeutics, Inc.

USPTO granted patent for oral non-opioid AV-101 covering neuropathic pain, expiring at least 2034.
Patent strengthens IP for AV-101 targeting disorders involving NMDA receptor, including pain and dyskinesias.
Preclinical data showed AV-101 similar efficacy to gabapentin/pregabalin with better side effect profile.
Phase 1 data in Journal of Pain indicated AV-101 well tolerated; allodynia/hyperalgesia reductions observed.
Vistagen plans to seek strategic partnerships for AV-101 development and commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.